



Recalcitrant vegetative and nodular scalp lesions on the vertex in pemphigus patients: an immunocompromised district?*

Dear Editor,

Although scalp involvement is common in patients with pemphigus vulgaris (PV) and pemphigus foliaceus (PF), vegetative scalp lesions have rarely been reported in PV patients.¹⁻⁵ Here we present two patients with mucocutaneous PV and one patient with PF who developed recalcitrant vegetative lesions and nodular lesions on the scalp during their disease course.

Among a total of 524 PV and PF patients followed up at the bullous disease outpatient clinic, only three (0.6%) developed recalcitrant vegetative and nodular lesions on the scalp (Figs. 1,2,5). The demographic, clinical, and immunopathological features and treatment characteristics of these three patients are shown in Table 1.

The first and second patients had a diagnosis of PV presenting with mucocutaneous involvement including scalp (Figs. 1,2). Four years following the diagnosis, a treatment-resistant, vegetative scalp lesion appeared on the right vertex of the first patient (Fig. 1a). The second patient also developed treatment-resistant scalp lesions, gradually becoming vegetative on the right and left vertex, two years after the diagnosis (Fig. 2a). In addition to the vegetative scalp lesions, non-compliance with therapy and frequent disease activations mostly occurring on these vegetative scalp lesions were other common features of these two patients. Despite the achievement of the clinical and immunological remission with treatment, residual vegetative masses on the scalp, associated with cicatricial alopecia in the first patient, remained in both of them (Figs. 1b, 2 b). The third patient had a diagnosis of PF presenting with cutaneous involvement including the scalp. An alopecic, nodular scalp lesion firstly appeared on the right vertex, three years following the diagnosis (Fig. 5a). At that time, he had a high level of anti-desmoglein-1 antibody titer (Table 1) without any other cutaneous involvement and the nodular scalp lesion showed a significant regression under intralesional corticosteroid treatment (Fig. 5b). Although scalp plaques were clinically vegetative in the first and second patients, histopathological examination performed at the time of disease activation in both patients revealed findings compatible with PV, rather than pemphigus vegetans (Figs. 3,4). Moreover, the classical intertriginous, vegetative, or papillomatous lesions of pemphigus vegetans were not observed in these two patients. Unfortunately, a histopathological examination of the scalp lesion could not be performed for PF patient.

Scalp involvement is reported in up to 60% of pemphigus patients in various series.^{1,2} However, vegetative scalp lesion has previously been reported in only three PV patients, to the best of our knowledge.³⁻⁵ All of the previously reported patients with vegetative scalp plaques

presented as a localized form of PV, unlike the present study's patients.³⁻⁵ The vegetative scalp lesions of PV patients occurred during treatment of recalcitrant disease course and particularly influenced by frequent disease activations. Additionally, to the best of our knowledge, a disease activation limited to a nodular, alopecic scalp lesion, as seen in the PF patient, has never been reported before. In both of the present study's PV patients, residual vegetative masses remained on the scalp despite the disease remission (Figs. 1b, 2 b). On the other hand, the nodular scalp lesion in our PF patient showed almost complete regression under intralesional corticosteroid treatment (Fig. 5b).

We think that these scalp lesions which were observed during the disease course may have occurred as a result of a hypertrophic healing process of the recalcitrant pemphigus lesions. Recently, the development of keratotic verrucous plaques on the trunk was reported in a patient with long-lasting PF which was resistant to various therapies, similar to the PV patients.⁶

Interestingly, the clinical appearance of the scalp lesions in all three patients were vegetative plaques and nodular lesions mainly localized on the right vertex. The other possible mechanism for the scalp lesions in the present study's patients may be explained by the "immunocompromised district" concept, proposed by Ruocco et al., which denotes a regional immune dysregulation characterized by either reduction or induction of immunity.⁷ One of the suggested pathophysiological mechanisms is that disruption of lymph circulation leads to trafficking of immune cells, inducing an altered immune response that can be excessive, favoring the outbreak of immune disorders.⁷ In the present study, the lymph circulation might be affected by long-lasting scalp lesions with hypertrophic healing, which might have given rise to an antigen burden on the vertex of the scalp, resulting in frequent disease activations followed by a repetitive healing process in a sort of vicious cycle. However, it is a matter of debate why these recalcitrant lesions vulnerable to disease activations were localized at similar sites in the patients.

In conclusion, the present PV and PF patients had scalp involvement with vegetative plaques and nodular lesions on the vertex, representing a distinct and rare clinical manifestation.

Financial support

None declared.

Authors' contributions

Rifkiye Kucukoglu: Critical literature review; data collection, analysis and interpretation; effective participation in research orientation; intellectual participation in propaedeutic and/or therapeutic management of studied cases; manuscript critical review; preparation and writing of the manuscript; study conception and planning.

Tugba Atci: Critical literature review; data collection, analysis and interpretation; effective participation in

* Study conducted at the Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.




Figure 1 PV Patient 1. (a) An alopecic vegetative plaque with erythema, erosions, and crusting, (b) A cicatricial alopecic verrucous plaque on the right vertex after remission of the disease.




Figure 2 PV Patient 2. (a) Vegetative scalp plaques with oozing, crusting, erosions and fissures, (b) Lobulated verrucous plaques on the right and left vertex of the scalp after remission of the disease.




Figure 3 (a) The biopsy shows acanthotic epidermis, suprabasal cleavage on both epidermis and all hair follicles (Hematoxylin & eosin, $\times 40$), (b) Epidermis and hair follicle epithelium showing suprabasal acantholysis, plasma cell-rich inflammatory infiltrate in surrounding dermis (Hematoxylin & eosin, $\times 200$).

research orientation; manuscript critical review; preparation and writing of the manuscript; study conception and planning.

Goncagul Babuna-Kobaner: Critical literature review; data collection, analysis and interpretation; effective participation in research orientation; manuscript critical review; preparation and writing of the manuscript; study conception and planning.

Nesimi Buyukbabani: Data collection, analysis and interpretation; effective participation in research orientation; intellectual participation in propaedeutic and/or therapeutic management of studied cases; manuscript critical review; preparation and writing of the manuscript; study conception and planning.

Table 1 Demographic, clinical, and laboratorial and treatment features of the pemphigus patients.

Variables	PV Patient 1	PV Patient 2	PF Patient 3
Age (years)/Sex	68/Male	63/Male	46/Male
Direct immunofluorescence	Intercellular deposition of IgG and C3 within epidermis Positive	Intercellular deposition of IgG and C3 within epidermis Positive	Intercellular deposition of IgG and C3 within epidermis Positive
Indirect immunofluorescence			
ELISA	ND	Desmoglein 3: 9.1 ^a Desmoglein 1: 5.3 ^a	Desmoglein3: negative Desmoglein1: 4.9 ^a
Diagnosis	Pemphigus vulgaris	Pemphigus vulgaris	Pemphigus foliaceus
Localization of vegetative/nodular scalp lesions	Right vertex	Right and left vertex	Right vertex
Cutaneous involvement (other than scalp)	+	+	+
Mucosal involvement	Oral	Oral and nasal	-
Treatment	SC, AZA, ILC	SC, AZA, MMF, Rituximab, IVIG, ILC	SC, AZA, ILC
Follow-up (years)	8	9	6

PV: pemphigus vulgaris; PF: pemphigus foliaceus; IgG, Immunoglobulin G; C3, Complement C3; ND; Not determined; SC, Systemic Corticosteroid; AZA, Azathioprine; ILC, Intralesional Corticosteroid; MMF, Mycophenolate Mofetil; IVIG, Intravenous Immunoglobulin; .

^a Cut-off value: 1 ratio.




Figure 4 (a) Panoramic view of the biopsy reveals extensive suprabasal acantholytic cleavage in nearly all hair follicles (Hematoxylin & eosin, $\times 40$), (b) High power view of suprabasal acantholysis in follicle epithelium, highly suggestive of pemphigus (Hematoxylin & eosin, $\times 200$).




Figure 5 (a) An alopecic nodule on the right vertex in PF patient, (b) Almost complete regression of the nodular lesion with only minimal alopecia.

Conflicts of interest

None declared.

References

- Sar-Pomian M, Konop M, Gala K, Rudnicka L, Olszewska M. Scalp involvement in pemphigus: a prognostic marker. Postepy Dermatol Alergol. 2018;35:293-8.
 - Sar-Pomian M, Rudnicka L, Olszewska M. The significance of scalp involvement in pemphigus: a literature review. Biomed Res Int. 2018;2018:6154397.
 - Lehrhoff S, Miller K, Fischer M, Kamino H, Meehan S. Localized pemphigus with vegetative features. Dermatol Online J. 2012;18:11.
 - Gu A, Zhang L, Xiao Y, Liang J. Pemphigus vulgaris with vegetating feature confined to the scalp. Int J Dermatol. 2018;57:e88-90.
 - Zaraa I, El Euch D, Kort R, et al. Localized pemphigus: a report of three cases. Int J Dermatol. 2010;49:715-6.
 - Ohashi T, Ohtsuka M, Kikuchi N, Yamamoto T. Verrucous variant of pemphigus foliaceus. Clin Exp Dermatol. 2020;45:584-5.
 - Ruocco V, Brunetti G, Puca RV, Ruocco E. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected, and otherwise damaged sites. J Eur Acad Dermatol Venereol. 2009;23:1364-73.
 - Rifkiye Kucukoglu  a, Tugba Atci  a,* , Goncagul Babuna-Kobaner  a, Nesimi Buyukbabani  b
- ^a Department of Dermatology & Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
^b Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Corresponding author.
E-mail: tugba.ertan@istanbul.edu.tr (T. Atci).
- Received 10 November 2021; accepted 7 January 2022
- <https://doi.org/10.1016/j.abd.2022.01.007>
0365-0596/ © 2022 Sociedade Brasileira de Dermatologia.
Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Sensitization to rubber allergens among 1,162 patients tested with the Brazilian standard battery*



Dear Editor,

Widespread sensitization to rubber components is well known and may be caused by latex or synthetic rubber additives. Other products, such as insecticides, clothing, medicines, and paints have similar chemical additives. Latex primarily causes type I and rubber vulcanizers and antioxidants are responsible for type IV allergies.^{1,2}

The Brazilian Standard Battery (BPP, *Bateria Padrão Brasileira*) features rubber mixtures (carba, thiuram, mercapto, PPD) and other related allergens, such as hydroquinone, ethylenediamine, and paraphenylenediamine (PPDA). Hydroquinone is an antioxidant, rarely used in industry at present.³ Ethylenediamine dihydrochloride stabilizes steroid creams and latex but it is not tested in other standard series.⁴ PPDA belongs to the benzene group and can cross-react with PPD-mix (*N*-Isopropyl-*N*-phenyl Paraphenylenediamine [IPPD], *N*-cyclohexyl-*N*-phenyl-*p*-phenylenediamine,*N,N*-diphenyl-*p*-phenylenediamine).⁵

From October 2009 to October 2018, 1,162 patients with suspected allergic contact dermatitis were treated at the Dermatology Annex of Hospital das Clínicas. They were tested with the BPP (FDA-allergenic, RJ, Brazil) using Finn chambers® (Oy, Finland) and readings were made at 48 hs and 96 hs, following the criteria of the ICDRG (International Contact Dermatitis Research Group).⁶ Data on age, occupation, affected sites, history of atopy, and allergen positivity were collected in Excel® throughout these years.

In this retrospective study, the data from the aforementioned worksheet were consulted and, when necessary, the medical records as well, to complement the necessary information.

A total of 120 patients (10.3%) tested positive for rubber allergens; of these, 98 (81.7%) were clinically relevant based on patient history and allergen exposure. The demographic characteristics were described according to the MOAHLFA index (Tables 1 and 2).

The prevalence of positivity for rubber mixtures was: carba, 41.7%; thiuram, 30%; mercapto, 15%; and PPD, 5% (Table 2).

An association between rubber allergens (cross-reactions) was observed in 35.8% of the cases: carbamates with thiurams in 16.6% and mercaptobenzothiazole with carbamates in 1.7%. Furthermore, the association between

Table 1 MOAHLFA* index in patients with positivity to rubber allergens.

	n (%)
M	59 (49,2)
O	61 (50,8) (40,8% – construction workers)
A	30 (25)
H	70 (50,8)
L	48 (40)
F	43 (34,2)
A	82 (68,3)

M, Male sex; O, Occupational Dermatitis; A, History of Atopy; H, Dermatitis of the hands; L, Dermatitis of the legs; F, Dermatitis of the face; A, age 40 years or older.

* Uter W, Schnuch A, Gefeller O, ESCD working group: European Surveillance System on Contact Allergies. Guidelines for the descriptive presentation and statistical analysis of contact allergy data. Contact Dermatitis. 2004;51:47-56.

* Study conducted at the Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.